84057-84-1 | Lamotrigine

Chemical type

• Antiseizure medication (ASM)

^[1,2]

• Phenyltriazine derivative

^[2]

Key properties

• Enters saliva by passive diffusion
• Reflects free unbound fraction in plasma
• Lower salivary and plasma concentrations associated with seizure freedom
• No significant association with adverse events
• Strong correlation between saliva and plasma levels (R² = 0.70)

^[1]

• Mechanism of action: blocks voltage-gated sodium channels (VGSCs), enhancing both fast and slow inactivation
• Low teratogenicity
• May have a dose-dependent dual action on sodium channels, which could explain its unique efficacy profile in IGE

^[2]

• Treatment of epilepsy to achieve seizure freedom
• Monotherapy or add-on therapy in polytherapy regimens
• Therapeutic drug monitoring (TDM) for efficacy and dosage adjustment

^[1]

• Treatment of Idiopathic Generalized Epilepsy (IGE)
• Most effective at moderate doses (201-400 mg/day); higher doses (>400 mg/day) were not associated with better seizure control and showed decreased efficacy

^[2]

Classification by use

• Antiepileptic drugs
• Chemicals used in neurological disorder management

^[1]

• Chemicals used as pharmaceuticals (anticonvulsants)
• Alternative to valproate, especially for females of childbearing age

^[2]

A trustworthy factory and manufacturer

Demei Chemical Technology Co., Ltd. is a modern high-tech enterprise integrating R&D, production, and sales. The company's founder, Dr. Arron, born in April 1975, graduated from the School of Mechanical Engineering at Yanshan University and has been engaged in research in the fields of mechanical engineering and chemical synthesis for many years. The company's products focus on the chemical industry, primarily dealing in chemical raw materials and chemical production machinery and equipment. With its strong technical capabilities, advanced production equipment, and strict quality management system, the company has earned the trust of customers worldwide.

1. [Cite:1] Is the salivary concentration of lamotrigine and levetiracetam associated with clinical outcome?, Epilepsy & Behavior, Volume 171, October 2025, 110595
2. [Cite:2] Dose–response analysis of valproate, levetiracetam and lamotrigine in idiopathic generalized epilepsy, Epilepsy & Behavior, Volume 177, April 2026, 110940